• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    22nd Century Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    10/24/24 6:05:22 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email
    false 0001347858 0001347858 2024-10-23 2024-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 23, 2024

     

     

    22nd Century Group, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Nevada 001-36338 98-0468420
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number) (I.R.S. Employer
    Identification No.)

     

    321 Farmington Road, Mocksville, North Carolina

    (Address of Principal Executive Office)

    27028

    (Zip Code)

     

    Registrant’s telephone number, including area code: (716) 270-1523

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading symbol Name of each exchange on which
    registered
    Common Stock, $0.00001 par value XXII NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ¨

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    PIPE Securities Purchase Agreement

     

    On October 23, 2024, 22nd Century Group, Inc. (the “Company”) and certain investors (the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) relating to the issuance and sale of prefunded warrants to purchase shares of common stock of the Company (the “Common Stock”) and warrants to purchase shares of Common Stock pursuant to a private placement (collectively, the “Offering”). The Investors purchased approximately $3 million of prefunded warrants and warrants, consisting of prefunded warrants to purchase an aggregate of 28,354,914 shares of Common Stock (the “Prefunded Warrants”) and warrants (the “Warrants”) to purchase an aggregate of 42,532,372 shares of Common Stock, at a purchase price of $0.10719 per Prefunded Warrant and accompanying Warrant. The Prefunded Warrants are immediately exercisable upon issuance. The Warrants are exercisable after the Stockholder Approval Date (as defined in the Securities Purchase Agreement) at an exercise price of $1.00 per share of common stock, expire on the date that is five (5) years after the Stockholder Approval Date and are subject to adjustment in certain circumstances, including upon any subsequent equity sales at a price per share lower than the then effective exercise price of such Warrants, then such exercise price shall be lowered to such price at which the shares were offered. The Offering is expected to close on October 24, 2024, subject to customary closing conditions.

     

    The Securities Purchase Agreement provides that, subject to certain exceptions, until 60 days after the effectiveness of the registration statement registering the Prefunded Warrants, the Warrants, and the shares of Common Stock issuable upon exercise of the Prefunded Warrants and the Warrants, neither the Company nor any of its subsidiaries will issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock equivalents. The Securities Purchase Agreement also provides that the Investors in the Offering have a right of participation in future equity or equity linked offerings by the Company for 9 months following the Closing Date (as defined in the Securities Purchase Agreement).

     

    The Securities Purchase Agreement provides that, subject to certain exceptions, for a period of one year after the effectiveness of the registration statement registering the Prefunded Warrants, the Warrants, and the shares of Common Stock issuable upon exercise of the Prefunded Warrants and the Warrants, the Company will be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of common stock or common stock equivalents (or a combination of units thereof) involving a Variable Rate Transaction (as defined in the Securities Purchase Agreement).

     

    The net proceeds to the Company from the Offering, after deducting the fees of Dawson James Securities, Inc. (the “Placement Agent”) and the Company’s estimated offering expenses, are expected to be approximately $2.9 million.

     

    The Prefunded Warrants and Warrants are being issued in a private placement and were exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on Section 4(a)(2) thereof as a transaction not involving a public offering and/or Rule 506 of Regulation D promulgated thereunder. The Company has agreed to file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing for the resale by the Investors of (i) the Prefunded Warrants and the shares of Common Stock issuable upon exercise of the Prefunded Warrants by November 1, 2024, and (ii) the Warrants and shares of Common Stock issuable upon exercise of the Warrants as soon as practicable.

     

    The shares issuable upon exercise of the Warrants are subject to stockholder approval. The Company has agreed to hold an annual or special meeting on or before May 30, 2025, to have stockholders approve the issuance of the shares of Common Stock underlying the Warrants pursuant to applicable Nasdaq rules.

     

    The Company will pay the Placement Agent a cash fee of $100,000, and will reimburse the Placement Agent for its expenses, including the reimbursement of legal fees up to an aggregate of $30,000. In addition, the Company agreed to issue placement agent warrants to purchase an aggregate of 2,268,393 shares of common stock (the “Placement Agent Warrants”) to the Placement Agent or its designees with substantially the same terms as the Warrants, except that the Placement Agent Warrants have an exercise price of $1.25.

     

     

     

     

    The foregoing summaries of the terms of the Securities Purchase Agreement, the Prefunded Warrants, the Warrants and the Placement Agent Warrants are subject to, and qualified in their entirety by, the forms of such documents attached hereto as Exhibits 10.1, 4.1, 4.2, and 4.3, respectively, and incorporated herein by reference. The Securities Purchase Agreement contains representations and warranties that the respective parties made to, and solely for the benefit of, the other parties thereto in the context of all of the terms and conditions of those agreements and in the context of the specific relationship between the parties. The provisions of the Securities Purchase Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreement or as stated therein and are not intended as a document for investors and the public to obtain factual information about the current state of affairs of the parties to the documents and agreements. Rather, investors and the public should look to other disclosures contained in the Company’s filings with the SEC.

     

    Item 3.02 Unregistered Sales of Equity Securities

     

    The disclosure required by this Item, and included in Item 1.01 of this Current Report, is incorporated herein by reference. The Prefunded Warrants, the Warrants, the Placement Agent Warrants and the shares of the Company’s Common Stock issuable upon exercise of the Prefunded Warrants, the Warrants and the Placement Agent Warrants have not been registered under the Securities Act, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

     

    Item 9.01(d): Financial Statements and Exhibits.

     

    Exhibit 4.1 Form of Prefunded Warrant
    Exhibit 4.2 Form of Warrant
    Exhibit 4.3 Form of Placement Agent Warrant
    Exhibit 10.1 Form of Securities Purchase Agreement, dated October 23, 2024, by and between 22nd Century Group, Inc. and each of the Purchasers (as defined therein).
    Exhibit 104 Cover Page Interactive Data File - The cover page XBRL tags are embedded within the inline XBRL document

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      22nd Century Group, Inc.
       
      /s/ Lawrence D. Firestone
    Date: October 23, 2024 Lawrence D. Firestone
      Chief Executive Officer

     

     

     

    Get the next $XXII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    SEC Filings

    View All

    22nd Century Group Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    1/22/26 8:00:48 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEF 14A filed by 22nd Century Group Inc.

    DEF 14A - 22nd Century Group, Inc. (0001347858) (Filer)

    12/30/25 5:19:44 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form PRE 14A filed by 22nd Century Group Inc.

    PRE 14A - 22nd Century Group, Inc. (0001347858) (Filer)

    12/19/25 4:30:24 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century CEO & Chairman Larry Firestone Provides 2025 Year-in-Review Letter to Stockholders

    MOCKSVILLE, N.C., Jan. 15, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today issued the following letter to stockholders from Lawrence Firestone, the Chief Executive Officer of 22nd Century Group, Inc.:  2025 Year-in-Review Shareholder Letter Dear Shareholders, 2025 was a pivotal year for 22nd Century Group, Inc. as we exited our multi-year restructuring, began advancing our strategic initiatives, strengthened our financial foundation, and reinforced our leadership position in tobacco harm reduction. In a complex regu

    1/15/26 9:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century to Participate in the Needham Annual Growth Conference January 16, 2026

    MOCKSVILLE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced that Larry Firestone, Chief Executive Officer, and Dan Otto, Chief Financial Officer, will present as part of the Needham Growth Conference taking place on Friday, January 16, 2026. The management team will be available for virtual one-on-one meetings. Investors interested in booking meetings can register for the conference and arrange a time through their Needham representative, or the Company's investor relations at investorrelation

    1/12/26 4:30:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Files VLN® MRTP Renewal – Only Combustible Tobacco Product Authorized by the FDA Specifically to Help Smokers Smoke Less

    VLN® Reduced Nicotine Content Tobacco Reduces Smoking and Increases Quit Attempts Per Clinical Data Multiple VLN® Based Cigarette Brands Expand Availability and Reach of Non-Addictive Alternative in the Fight Against The Harms of Smoking MOCKSVILLE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the filing of its Modified Risk Tobacco Product renewal application for its innovative VLN® reduced nicotine content products, the first and still the only combustible cigarette authorized by the U.S

    1/6/26 6:10:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arno Andrew was granted 17,295 shares, increasing direct ownership by 9,298% to 17,481 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/14/25 4:58:49 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    EVP of Sales and Marketing Manfredonia Robert P was granted 32,429 shares, increasing direct ownership by 5,123% to 33,062 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/13/25 5:40:01 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    VP and Deputy General Counsel Staffeldt Jonathan was granted 37,146 shares, increasing direct ownership by 5,124% to 37,871 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/13/25 5:38:22 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    1/8/24 8:04:11 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

    Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    7/21/22 9:12:19 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on 22nd Century Group with a new price target

    Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    6/15/22 7:42:24 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Roth Capital initiated coverage on 22nd Century Group with a new price target

    Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

    3/8/22 9:21:23 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces Resignation of John Miller as President of Tobacco

    Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

    5/30/24 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

    BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

    9/12/22 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Reports Third Quarter 2025 Financial Results

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Second Quarter 2025 Financial Results

    VLN® Early Adoption Commercial Activity Expands with Two Partner Brand Launches in Progress – Smoker Friendly and Pinnacle Commenced Pinnacle VLN® Stocking Shipments for Almost 1,000 Locations of Top-5 C-Store Customer, Additional Locations to Come Significantly Expanded State Authorizations for both Reduced Nicotine Content and Conventional Products High Margin Branded Products Business Model Set to Grow Profitably MOCKSVILLE, N.C., Aug. 14, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for th

    8/14/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports First Quarter 2025 Financial Results

    Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories  Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announ

    5/13/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by 22nd Century Group Inc.

    SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

    10/23/24 7:27:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care